Kalaris Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
KLRS Nasdaq 2836 kalaristx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Kalaris Therapeutics, Inc.

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement - Dec 17th, 2025 3:59 pm
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD - Dec 17th, 2025 2:01 pm
We Think Kalaris Therapeutics (NASDAQ:KLRS) Needs To Drive Business Growth Carefully - Nov 27th, 2025 5:58 am
Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference - Nov 24th, 2025 6:00 am
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates - Nov 12th, 2025 6:00 am
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer - Nov 3rd, 2025 5:30 am
Kalaris to Present at Stifel 2025 Annual Healthcare Conference - Oct 30th, 2025 6:00 am
Kalaris Therapeutics, Inc.'s (NASDAQ:KLRS) biggest owners are private equity firms who got richer after stock soared 24% last week - Sep 28th, 2025 7:44 am
UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration - Sep 15th, 2025 1:26 pm
Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration - Sep 15th, 2025 6:00 am
Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know - Sep 1st, 2025 10:00 am
Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates - Aug 13th, 2025 6:00 am
We're Hopeful That Kalaris Therapeutics (NASDAQ:KLRS) Will Use Its Cash Wisely - Jun 20th, 2025 6:46 am
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference - Jun 2nd, 2025 6:00 am
Kalaris to Participate at Stifel Ophthalmology Forum - May 23rd, 2025 9:03 am
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights - May 14th, 2025 6:00 am
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee - Apr 4th, 2025 6:00 am
Kalaris Announces Closing of Merger with AlloVir - Mar 18th, 2025 2:21 pm